Cue Biopharma (CUE) Earnings
Cue Biopharma's next earnings report is expected on Wednesday, November 11, 2026, with EPS expected around -4.04.
Summary
In the quarter ended June 2026, Cue Biopharma had revenue of $8M, up 166.7% on a year earlier, and diluted EPS of -24.14.
On August 14, 2026 it reported EPS of -13.81.
Report dates
| Report | Date | Time | EPS estimate | EPS reported | Result |
|---|---|---|---|---|---|
| Next | Wed Nov 11, 2026 | — | -4.04 | — | — |
| Last | Fri Aug 14, 2026 | — | — | -13.81 | — |
Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.
Also reporting the week of November 9
| Company | Date | Time |
|---|---|---|
| Berkshire Hathaway Inc BRK-B | Mon Nov 9 | Reported |
| Cisco Systems Inc CSCO | Thu Nov 12 | After close |
| Applied Materials Inc AMAT | Thu Nov 12 | After close |
| Brookfield Corp BN | Thu Nov 12 | Before open |
| Constellation Energy Corp CEG | Mon Nov 9 | Reported |
| KKR & Co. Inc. KKR | Mon Nov 9 | Reported |
| Transdigm Group Incorporated TDG | Tue Nov 10 | Before open |
| Barrick Mining Corporation B | Mon Nov 9 | Reported |
Quarterly results
The last 12 quarters from Cue Biopharma's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.
| Quarter ended | Revenue | Growth | EPS (diluted) | Growth | Op. margin | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | $8M | +166.7% | -24.14 | — | -1113.3% | 2026-08-14 |
| Mar 31, 2026 | $6M | +1250.6% | -1.08 | — | -94.1% | 2026-05-14 |
| Dec 31, 2025 | $22M | +1292.3% | — | — | 9.0% | 2026-03-16 |
| Sep 30, 2025 | $2M | -35.6% | -2.10 | — | -353.4% | 2025-11-12 |
| Jun 30, 2025 | $3M | +11.1% | -2.67 | — | -292.3% | 2025-08-12 |
| Mar 31, 2025 | $421,000 | -75.5% | -4.95 | — | -2921.4% | 2025-05-12 |
| Dec 31, 2024 | $2M | -13.5% | — | — | -611.2% | 2025-03-31 |
| Sep 30, 2024 | $3M | +58.9% | -5.10 | — | -264.2% | 2024-11-14 |
| Jun 30, 2024 | $3M | +92.3% | -6.00 | — | -390.6% | 2024-08-14 |
| Mar 31, 2024 | $2M | +818.2% | -7.50 | — | -737.8% | 2024-05-09 |
| Dec 31, 2023 | $2M | +1106.0% | — | — | -759.6% | 2024-03-28 |
| Sep 30, 2023 | $2M | +2988.2% | -7.20 | — | -543.8% | 2023-11-03 |
Questions about Cue Biopharma
When does Cue Biopharma report earnings?
Cue Biopharma's next earnings report is expected on November 11, 2026.
How did Cue Biopharma do last quarter?
In the quarter ended June 2026, Cue Biopharma had revenue of $8M, up 166.7% on a year earlier, and diluted EPS of -24.14.
From Cue Biopharma's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.